Page 3 - Jay Feingold News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Operator Good morning, and welcome to the ADC Therapeutics first-quarter results 2021 financial call. My name is Cheryl, and I will be your operator for today's call. [Operator instructions] I will now turn the call over to Amanda Hamilton, you may begin. Amanda Hamilton -- Manager, Investor Relations Thank you, operator. This morning, we issued a press release announcing our first-quarter 2021 financial results and business update. This release is available on the ADCT website at ir.adctherapeutics.com under the Press Releases section. On today's call, Chris Martin, chief executive officer;...

Search jobs 05-May-2021 ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas - ZYNLONTA is the first and only CD19-targeted ADC approved as a single-agent treatment for adult patients with r/r DLBCL LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, t...

 |  0  ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA (loncastuximab tesirine-lpyl) has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines) in oncology for B-cell Lymphomas. Specifically, the NCCN Guidelines now include ZYNLONTA as a category 2A designation as a treatment option for adult patients wi...

(2) - ZYNLONTA is the first and only CD19-targeted ADC approved as a single-agent treatment for adult patients with r/r DLBCL ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA (loncastuximab tesirine-lpyl) has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines) in oncology for B-cell Lymphomas. Specifically, the NCCN Guidelines now include ZYNLONTA as a category 2A ...